OBJECTIVE: Randomized trials generally use "frequentist" statistics based on P-values and 95% confidence intervals. Frequentist methods have limitations that might be overcome, in part, by Bayesian inference. To illustrate these advantages, we re-analyzed randomized trials published in four general medical journals during 2004. STUDY DESIGN AND SETTING: We used Medline to identify randomized superiority trials with two parallel arms, individual-level randomization and dichotomous or time-to-event primary outcomes. Studies with P<0.05 in favor of the intervention were deemed "positive"; otherwise, they were "negative." We used several prior distributions and exact conjugate analyses to calculate Bayesian posterior probabilities for clinically relevant effects. RESULTS: Of 88 included studies, 39 were positive using a frequentist analysis. Although the Bayesian posterior probabilities of any benefit (relative risk or hazard ratio<1) were high in positive studies, these probabilities were lower and variable for larger benefits. The positive studies had only moderate probabilities for exceeding the effects that were assumed for calculating the sample size. By comparison, there were moderate probabilities of any benefit in negative studies. CONCLUSION: Bayesian and frequentist analyses complement each other when interpreting the results of randomized trials. Future reports of randomized trials should include both.
OBJECTIVE: Randomized trials generally use "frequentist" statistics based on P-values and 95% confidence intervals. Frequentist methods have limitations that might be overcome, in part, by Bayesian inference. To illustrate these advantages, we re-analyzed randomized trials published in four general medical journals during 2004. STUDY DESIGN AND SETTING: We used Medline to identify randomized superiority trials with two parallel arms, individual-level randomization and dichotomous or time-to-event primary outcomes. Studies with P<0.05 in favor of the intervention were deemed "positive"; otherwise, they were "negative." We used several prior distributions and exact conjugate analyses to calculate Bayesian posterior probabilities for clinically relevant effects. RESULTS: Of 88 included studies, 39 were positive using a frequentist analysis. Although the Bayesian posterior probabilities of any benefit (relative risk or hazard ratio<1) were high in positive studies, these probabilities were lower and variable for larger benefits. The positive studies had only moderate probabilities for exceeding the effects that were assumed for calculating the sample size. By comparison, there were moderate probabilities of any benefit in negative studies. CONCLUSION: Bayesian and frequentist analyses complement each other when interpreting the results of randomized trials. Future reports of randomized trials should include both.
Authors: John A Harvin; Rondel Albarado; Van Thi Thanh Truong; Charles Green; Jon E Tyson; Claudia Pedroza; Charles E Wade; Lillian S Kao Journal: J Am Coll Surg Date: 2021-01-21 Impact factor: 6.113
Authors: Angela L Stotts; Charles Green; Akihiko Masuda; John Grabowski; Kelly Wilson; Thomas F Northrup; F Gerard Moeller; Joy M Schmitz Journal: Drug Alcohol Depend Date: 2012-03-15 Impact factor: 4.492
Authors: Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta Journal: Stroke Date: 2017-05-15 Impact factor: 7.914
Authors: Joshua L Gowin; Charles E Green; Joseph L Alcorn; Alan C Swann; F Gerard Moeller; Scott D Lane Journal: J Psychopharmacol Date: 2011-07-05 Impact factor: 4.153
Authors: Paul M Cinciripini; Charles E Green; Jason D Robinson; Maher Karam-Hage; Jeffrey M Engelmann; Jennifer A Minnix; David W Wetter; Francesco Versace Journal: Psychopharmacology (Berl) Date: 2017-03-08 Impact factor: 4.530
Authors: Joyce P Samuel; Jon E Tyson; Charles Green; Cynthia S Bell; Claudia Pedroza; Don Molony; Joshua Samuels Journal: Pediatrics Date: 2019-03-06 Impact factor: 7.124
Authors: Craig A Beam; Colleen MacCallum; Kevan C Herold; Diane K Wherrett; Jerry Palmer; Johnny Ludvigsson Journal: Diabetologia Date: 2016-10-04 Impact factor: 10.122